Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells

Endocrine-Related Cancer

Volumn 18, Issue 4, 2011, Pages 451-464

  Zheng, Yichun ^a,b   Izumi, Koji ^a   Yao, Jorge L ^a   Miyamoto, Hiroshi ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYFLUTAMIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SHORT HAIRPIN RNA;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYSTECTOMY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL PROLIFERATION; DIHYDROTESTOSTERONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 80052176871     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0010     Document Type: Article

References (53)

1. Anderson D, Koch CA, Grey L, Ellis C, Moran MF &Pawson T 1990 Binding of SH2 domains of phospholipase C gamma 1, GAP, and Src to activated growth factor receptors. Science 250 979-982. (doi:10.1126/science.2173144)
2. Bacus SS, Chin D, Yarden Y, Zelnick CR & Stern DF 1996 Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. American Journal of Pathology 148 549-558. (Pubitemid 26056739)
3. Bellmunt J, Hussain M & Dinney CP 2003 Novel approaches with targeted therapies in bladder cancer: therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Critical Reviews in Oncology/- Hematology 46 (Suppl) S85-S104. (doi:10.1016/S1040-8428(03)00067-2)
4. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC & Loda M 2006 Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Research 66 5723-5728. (doi:10.1158/0008-5472.CAN- 05-3928)
5. Bhuvaneswari R, Gan YY, Soo KC & Olivo M 2009 Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Molecular Cancer 8 94. (doi:10.1186/1476-4598-8-94)
6. Black PC, Agarwal PK & Dinney CPN 2007 Targeted therapies in bladder cancer - an update. Urologic Oncology 25 433-438. (doi:10.1016/j.urolonc.2007. 05.011)
7. Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK & Scherr DS 2004 Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64 383-388. (doi:10.1016/j.urology.2004. 03.025)
8. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ & Tindall DJ 2009 Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocrine-Related Cancer 16 123-137. (doi:10.1677/ERC-08-0124)
9. Brass A, Barnard J, Patai B, Salvi D & Rukstalis DB 1995 Androgen upregulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Research 55 3197-3203.
10. Brys M, Stawinska M, Foksinski M, Barecki A, Zydek C, Miekos E & Krajewska WM 2004 Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms. Oncology Reports 11 219-224.
11. Canacci AM, Izumi K, Zheng Y, Gordetsky J, Yao JL &Miyamoto H 2011 Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate 71 1108-1114. (doi:10.1002/pros.21323)
12. Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN &Rosenfeld MG 1987 Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 328 820-823. (doi:10.1038/328820a0)
13. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285. (doi:10.1038/6495)
14. Craven RJ, Lightfoot H & Cance WG 2003 A decade of tyrosine kinases: from gene discovery to therapeutics. Surgical Oncology 12 39-49. (doi:10.1016/S0960-7404(03)00004-5)
15. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
16. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G et al. 2002 Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clinical Cancer Research 8 3438-3444. (Pubitemid 35340719)
17. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA et al. 1998 Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. PNAS 95 12022-12027. (doi:10.1073/pnas.95.20.12022)
18. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS & Wilson EM 2004 Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. Journal of Biological Chemistry 279 7119-7130. (doi:10.1074/jbc.M307649200)
19. Hartge P, Harvey EB, Linehan MW, Silverman DT, Sullivan JW & Hoover RN 1990 Unexplained excess risk of bladder cancer in men. Journal of the National Cancer Institute 82 1636-1640. (doi:10.1093/jnci/82.20.1636)
20. Itoh N, Patel U & Skinner MK 1998 Developmental and hormonal regulation of transforming growth factoralpha and epidermal growth factor receptor gene expression in isolated prostatic epithelial and stromal cells. Endocrinology 139 1369-1377. (doi:10.1210/en.139.3.1369)
21. Jemal A, Siegel R, Xu J & Ward E 2010 Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 60 277-300. (doi:10.3322/caac.20073)
22. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr & Grignon DJ 2001 Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clinical Cancer Research 7 2440-2447. (Pubitemid 32751647)
23. Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM & Reeder JE 2008 Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urology 8 7. (doi:10.1186/1471-2490-8-7)
24. Karlou M, Saetta AA, Korkolopoulou P, Levidou G, Papanastasiou P, Boltetsou E, Isaiadis D, Pavlopoulos P, Thymara I, Thomas-Tsagli E et al. 2009 Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. Pathology 41 327-334. (doi:10.1080/00313020902885011)
25. Knowles MA, Platt FM, Ross RL & Hurst CD 2009 Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer and Metastasis Reviews 28 305-316. (doi:10.1007/s10555-009-9198-3)
26. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA &Bartlett JM 2004 HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? European Journal of Cancer 40 56-63. (doi:10.1016/j.ejca.2003.08.027)
27. Lin H-K, Hu Y-C, Yang L, Altuwaijri S, Chen Y-T, Kang H-Y & Chang C 2003 Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. Journal of Biological Chemistry 278 50902-50907. (doi:10.1074/jbc.M300676200)
28. Lipponen P & Eskelinen M 1994 Expression of epidermal growth factor receptorin bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. British Journal of Cancer 69 1120-1125. (doi:10.1038/bjc.1994.220)
29. Liu Y, Majumder S, McCall W, Sartor CI, Mohler JL, Gregory CW, Earp HS & Whang YE 2005 Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Research 65 3404-3409. (doi:10.1158/0008-5472.CAN-04-4292)
30. MacLaine NJ, Wood MD, Holder JC, ReesRW&Southgate J 2008 Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Molecular Cancer Research 6 53-63. (doi:10.1158/1541-7786.MCR-07-0134)
31. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J &Sawyers CL 2004 HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 517-527. (doi:10.1016/j.ccr.2004.09.031)
32. Micello D, Marando A, Sahnane N, Riva C, Capella C &Sessa F 2010 Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Archiv 457 467-476. (doi:10.1007/s00428-010-0964-y)
33. Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C et al. 2010 Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU International [in press]. (doi:10.1111/j.1464-410X.2010.09834.x)
34. Miyamoto H, Kubota Y, Noguchi S, Takase K, Matsuzaki J, Moriyama M, Takebayashi S, Kitamura H & Hosaka M 2000 c-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55 679-683. (doi:10.1016/S0090-4295(99)00604-4)
35. Miyamoto H, Marwah P, Marwah A, Lardy H & Chang C 2003 3b-Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. PNAS 100 4440-4444. (doi:10.1073/pnas. 0831001100)
36. Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J, Hu Y-C, Tsai M-Y et al. 2007 Promotion of bladder cancer development and progression by androgen receptor signals. Journal of the National Cancer Institute 99 558-568. (doi:10.1093/jnci/djk113)
37. Mukherjee B & Mayer D 2008 Dihydrotestosterone interacts EGFR/MAPK signaling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. International Journal of Oncology 33 623-629.
38. Naderi A & Hughes-Davies L 2008 A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10 542-548. (doi:10.1593/neo.08274)
39. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR &Harris AL 1990 The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65 1619-1625. (doi:10.1002/1097-0142(19900401)65:7〈1619::AID- CNCR2820650728〉3.0.CO;2-Q)
40. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L & Lin B 2002 The program of androgen-responsive genes in neoplastic prostate epithelium. PNAS 99 11890-11895. (doi:10.1073/pnas.182376299)
41. Orio F Jr, Terouanne B, Georget V, Lumbroso S, Avances C, Siatka C & Sultan C 2002 Potentialaction of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Molecular and Cellular Endocrinology 198 105-114. (doi:10.1016/S0303-7207(02) 00374-X)
42. Orlando C, Sestini R, Vona G, Pinzani P, Bianchi S, Giacca M, Pazzagli M & Selli C 1996 Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. Journal of Urology 156 2089-2093. (doi:10.1016/S0022-5347(01)65441-7)
43. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW & Lee KS 2010 Expression of androgen receptors in primary breast cancer. Annals of Oncology 21 488-492. (doi:10.1093/annonc/mdp510)
44. Perry JE & Tindall DJ 1996 Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP. Cancer Research 56 1539-1544. (Pubitemid 26104016)
45. Pignon J-C, Koopmansch B, Nolens G, Delacroix L, Waltregny D & Winkler R 2009 Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Research 69 2941-2949. (doi:10.1158/0008-5472.CAN-08-3760)
46. Quandt K, Frech K, Karas H, Wingender E & Werner T 1995 MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Research 23 4878-4884. (doi:10.1093/nar/23.23.4878)
47. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J & Cordon-Cardo C 1995 Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clinical Cancer Research 1 545-550.
48. Schultz L, Albadine R, Hicks J, Jadallah S, Demarzo AM, Chen YB, Neilsen ME, Gonzalgo ML, Sidransky D, Schoenberg M et al. 2011 Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 116 5517-5526. (doi:10.1002/cncr.25502)
49. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L et al. 2000 Her-2-neu expression and progression toward androgen independence in human prostate cancer. Journal of the National Cancer Institute 92 1918-1925. (doi:10.1093/jnci/92.23.1918)
50. Traish AM & Morgentaler A 2009 Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. British Journal of Cancer 101 1949-1956. (doi:10.1038/sj.bjc.6605376)
51. Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M & Sertcelik N 2011 Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urologic Oncology 29 43-51. (doi:10.1016/j.urolonc.2009.01.033)
52. Wu X, Obata T, Highshaw RA, De Vere White R &Sweeney C 2004 The phosphatidylinositol-3 kinase regulates bladder cancer cell invasion. BJU International 93 143-150. (doi:10.1111/j.1464-410X.2004.04574.x)
53. Wu J-T, Han B-M, Yu S-Q, Wang H-P & Xia S-J 2010 Androgen receptor is a potential therapeutic target for bladder cancer. Urology 75 820-827. (doi:10.1016/j.urology.2009.10.041)